InterCept Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 42 Posts
1 2 3
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich Friday, January 26, 2018 6:44 PM EDT
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
Oppenheimer Downgrades Intercept Despite Two-Day Share Collapse
Article By: The Fly Friday, September 22, 2017 2:23 PM EDT
Oppenheimer analyst Jay Olson downgraded this afternoon shares of Intercept Pharmaceuticals to Perform from Outperform.
In this article: ICPT
Read
Technicals Always Don’t Work Out The Way You Would Expect
Article By: Bespoke Investment Group Friday, September 22, 2017 11:42 AM EDT
At the most recent trading day shown, the stock broke out above resistance to a new medium-term high. Not only that, but volume on the day of the breakout was also strong, coming in at twice the 50-day moving average.
In this article: ICPT
Read
Citi Calls FDA Communication 'New Negative' For Intercept Shares
Article By: The Fly Thursday, September 21, 2017 7:45 PM EDT
ICPT stock in afternoon trading was down 18%.
In this article: ICPT
Read
Intercept Slides As Analyst Calls CymaBay Drug 'True Contender' After Data
Article By: The Fly Monday, July 17, 2017 3:33 PM EDT
Shares of Intercept Pharmaceuticals are sliding after H.C. Wainwright analyst Ed Arce raised his price target for its competitor CymaBay Therapeutics following data from the company's Phase 2 study of seladelpar in primary biliary cholangitis.
In this article: ICPT Also: CBAY
Read
Good Day Today: XBI Breaks Through To YTD Highs
Article By: Rod Raynovich Monday, June 19, 2017 9:31 PM EDT
Tech stocks rebounded today and biotech stocks soared and maintained the market lead in 2017 performance.
In this article: BMY, ALNY, BMRN, INCY, QQQ, AMGN, CLVS, GILD, XBI, XLV, ICPT, BLUE, RDUS, IBB
Read
Biotech Rally Clipped By Trump Tweet; ACA Makeover Creates Uncertainty
Article By: Rod Raynovich Wednesday, March 8, 2017 2:00 AM EDT
Just as investors were becoming more enthusiastic with biotechnology investing, a barrage of tweets and news stories regarding the ACA overhaul by Republicans cooled the market.
In this article: RHHBY, FBIOX, ALXN, ARRY, BMRN, IBB, REGN, ALKS, XBI, XLV, ICPT, ABBV, FMI, AUPH
Read
Rayno BioBeat 2017 #2: Biotech Breakthrough Rally
Article By: Rod Raynovich Monday, February 27, 2017 11:09 PM EDT
Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance.
In this article: RHHBY, ALNY, ARRY, BMRN, IBB, REGN, SGEN, BIIB, CLVS, VRTX, XBI, ICPT, BLUE, FMI, TSRO
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Article By: Arpita Dutt Thursday, September 22, 2016 1:45 PM EDT
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
In this article: ICPT, CNAT, GALT, ENTA, GLMD Also: AGN
Read
Intercept Pharmaceuticals Announces Public Offering Of Convertible Senior Notes
Article By: NASDAQ GlobeNewswire Wednesday, June 29, 2016 6:03 PM EDT
Intercept Pharmaceuticals, Inc. announced today that it has commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes.
In this article: ICPT
Read
Intercept Granted Accelerated Approval From FDA For PBC Treatment
Article By: The Fly Monday, May 30, 2016 8:16 AM EDT
Late Friday, Intercept Pharmaceuticals announced that the FDA has granted accelerated approval to Ocaliva, or obeticholic acid, for the treatment of primary biliary cholangitis.
In this article: ICPT
Read
E FDA Panel Backs Intercept's Liver Disease Drug
Article By: Terry Chrisomalis Thursday, April 7, 2016 7:42 PM EDT
Its Gastrointestinal Drugs Advisory Committee accepts surrogate endpoint and votes 17-0 to support approval of Intercept's drug for primary biliary cirrhosis.
In this article: ICPT
Read
What To Watch On Wall Street This Week: Intercept Pharmaceuticals, Tesla Motors And Walgreens Boots Alliance
Article By: TipRanks Sunday, April 3, 2016 6:25 PM EDT
This week Intercept Pharmaceuticals Inc meets the FDA to discuss a pipeline drug and analysts weigh in on Tesla Motors Inc following the Model 3 reveal. Lastly, don’t miss out as Walgreens Boots Alliance Inc announces earnings on Tuesday morning.
In this article: TSLA, ICPT, WBA
Read
Premarket Biotech Digest 2016-03-31: VRX Debt, OPK RAYALDEE NDA, ICPT Presentation
Article By: KKD Healthcare Analytics Thursday, March 31, 2016 9:10 AM EDT
Daily premarket biotech digest for March 31, 2016.
In this article: AGN, JNJ, OPK, PFE, VRX, ACAD, ANAC, ICPT, SRPT, GLMD, CTRV, BVXV, TKPYY
Read
View From The Hill: October 28, 2015
Article By: Hillbent Thursday, October 29, 2015 12:15 AM EDT
Today’s trading was most definitely data dependent and this one was solely dependent upon the Federal Reserve’s latest announcement to leave interest rates unchanged.
In this article: CAB, CBI, H, HOT, RAD, WSO, WEX, AAPL, AKAM, GLD, OIL, USO, VNTV, ICPT, SPX, VIX
Read
Intercept Pharmaceuticals Loses More Momentum As Morgan Stanley Weighs
Article By: Dr. Duru Thursday, August 13, 2015 10:00 PM EDT
Morgan Stanley initiated coverage on Intercept Pharmaceuticals, Inc. with an underweight rating. The negativity weighed on the stock for a 7.9% loss that sent the stock below critical support at its 200-day moving average.
In this article: MS, ICPT
Read
1 to 16 of 42 Posts
1 2 3